Mumbai, January 21, 2026 Lupin Limited (NSE: LUPIN, BSE: 500257) on Wednesday announced a strategic licensing and supply partnership with Spain based Galenicum Health to expand the reach of injectable Semaglutide across 23 international markets, strengthening its global diabetes and obesity portfolio.Under the agreement, the collaboration will be executed through Lupin’s subsidiary Lupin Atlantis Holdings SA. Galenicum will be responsible for the development, manufacturing and supply of finished dosage formulations, while Lupin will lead commercialisation, distribution and market expansion across regions including Canada, Europe, Southeast Asia and Latin America.Semaglutide is a GLP-1 receptor agonist widely prescribed for the...